Fecal Microbiota Transplant for Relapsing Clostridium difficile Infection Using a Frozen Inoculum From Unrelated Donors: A Randomized, Open-Label, Controlled Pilot Study
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Recurrent Clostridium difficile infection (CDI) with poor response to standard antimicrobial therapy is a growing medical concern. We aimed to investigate the outcomes of fecal microbiota transplant (FMT) for relapsing CDI using a frozen suspension from unrelated donors, comparing colonoscopic and nasogastric tube (NGT) administration. METHODS: Healthy volunteer donors were screened and a frozen fecal suspension was generated. Patients with relapsing/refractory CDI were randomized to receive an infusion of donor stools by colonoscopy or NGT. The primary endpoint was clinical resolution of diarrhea without relapse after 8 weeks. The secondary endpoint was self-reported health score using standardized questionnaires. RESULTS: A total of 20 patients were enrolled, 10 in each treatment arm. Patients had a median of 4 (range, 2-16) relapses prior to study enrollment, with 5 (range, 3-15) antibiotic treatment failures. Resolution of diarrhea was achieved in 14 patients (70%) after a single FMT (8 of 10 in the colonoscopy group and 6 of 10 in the NGT group). Five patients were retreated, with 4 obtaining cure, resulting in an overall cure rate of 90%. Daily number of bowel movements changed from a median of 7 (interquartile range [IQR], 5-10) the day prior to FMT to 2 (IQR, 1-2) after the infusion. Self-ranked health score improved significantly, from a median of 4 (IQR, 2-6) before transplant to 8 (IQR, 5-9) after transplant. No serious or unexpected adverse events occurred. CONCLUSIONS: In our initial feasibility study, FMT using a frozen inoculum from unrelated donors is effective in treating relapsing CDI. NGT administration appears to be as effective as colonoscopic administration. CLINICAL TRIALS REGISTRATION: NCT01704937.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In a pilot open-label randomized trial, frozen FMT by nasogastric tube appeared to be as effective as colonoscopic administration in resolving CDIassociated diarrhea. 126”
From Key determinants of success in fecal microbiota transplantation: From microbiome to clinic (2023) · cites this paper as [126]
In the citing paper
“Youngster et al. conducted a randomized pilot study comparing upper and lower GI routes of FMT, and the report found a non-significant difference in cure rate between the two different administration methods.67”
From Fecal microbiota transplantation: Review and update (2019) · cites this paper as [67]
In the citing paper
“FMT has been examined in both young and old, patients with limited comorbidities as well as those considered to be immunocompromised,43 and the procedure has been shown to be safe, well-tolerated, and effective.”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [43]
In the citing paper
“Furthermore, flares of FMT in patients with both UC and CD have been described,43, 75, 76 raising important questions around safety and the potential to worsen disease in some patients.”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [43]
In the citing paper
“These include complications of endoscopy, such as perforation and bleeding, and side effects related to sedation, such as aspiration43.”
From Update on Fecal Microbiota Transplantation 2015: Indications, Methodologies, Mechanisms, and Outlook (2015) · cites this paper as [43]
5 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms
Caporaso, J. G., Lauber, C. L., Walters, W. A., Berg-Lyons, D., Huntley, J., Fierer, N., Owens, S. M., Betley, J., Fraser, L., Bauer, M., et al. (2012) · The ISME Journal · doi:10.1038/ismej.2012.8 · Cited by 8,839 · cited 1×
“DNA was extracted and the V4 region of the 16S gene was sequenced using an Illumina MiSeq (Illumina, San Diego, CA) as described previously [30].”
MethodDuodenal Infusion of Donor Feces for Recurrent Clostridium difficile
van Nood, E., Vrieze, A., Nieuwdorp, M., Fuentes, S., Zoetendal, E. G., de Vos, W. M., Visser, C. E., Kuijper, E. J., Bartelsman, J. F. W. M., Tijssen, J. G. P., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1205037 · Cited by 3,708
TROTTI, A., COLEVAS, A., SETSER, A., RUSCH, V, JAQUES, D., BUDACH, V, LANGER, C., MURPHY, B., CUMBERLIN, R., & COLEMAN, C. (2003) · Seminars in Radiation Oncology · doi:10.1016/s1053-4296(03)00031-6 · Cited by 2,569 · cited 1×
“0 [26] approved by the FDA and institutional review board (IRB).”
BackgroundFidaxomicin versus Vancomycin for Clostridium difficile Infection
Louie, T. J., Miller, M. A., Mullane, K. M., Weiss, K., Lentnek, A., Golan, Y., Gorbach, S., Sears, P., & Shue, Y.-K. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa0910812 · Cited by 1,585 · cited 1×
“recurrence exceeds 60% with antimicrobial therapy [3, 5–8].”
BackgroundClostridium difficile infection: new developments in epidemiology and pathogenesis
Rupnik, M., Wilcox, M. H., & Gerding, D. N. (2009) · Nature Reviews Microbiology · doi:10.1038/nrmicro2164 · Cited by 1,380 · cited 1×
“The emergence of a virulent strain of the organism (NAP1/BI/027) has been associated with even higher rates of treatment failure [9,10].”
BackgroundClostridium difficile— More Difficult Than Ever
Kelly, C. P., & LaMont, J. T. (2008) · New England Journal of Medicine · doi:10.1056/nejmra0707500 · Cited by 1,313 · cited 1×
“In the United States the incidence of CDI has tripled over the last 15 years [3].”
BackgroundDecreased Diversity of the Fecal Microbiome in Recurrent Clostridium difficile–Associated Diarrhea
Chang, J. Y., Antonopoulos, D. A., Kalra, A., Tonelli, A., Khalife, W. T., Schmidt, T. M., & Young, V. B. (2008) · The Journal of Infectious Diseases · doi:10.1086/525047 · Cited by 1,010 · cited 1×
“Failure to reconstitute normal flora was shown to be a factor in severe, recurrent, and prolonged illness [13].”
BackgroundTreating Clostridium difficile infection with fecal microbiota transplantation
Bakken, J. S., Borody, T., Brandt, L. J., Brill, J. V., Demarco, D. C., Franzos, M. A., Kelly, C., Khoruts, A., Louie, T., Martinelli, L. P., et al. (2011) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2011.08.014 · Cited by 1,003 · cited 1×
“5 guidelines [26] by a relapse of CDI after having at least three episodes of mild-to-moderate CDI and failure of a 6-8 week taper with vancomycin with or without an alternative antibiotic, OR, at least two episodes of severe CDI resulting in hospitalization and associated with significant morbidity.”
BackgroundSelf-citationKassam, Z., Lee, C. H., Yuan, Y., & Hunt, R. H. (2013) · American Journal of Gastroenterology · doi:10.1038/ajg.2013.59 · Cited by 904 · cited 1×
“Another inhibiting factor is the fact that the available data are mostly based on retrospective case series and include only a single randomized trial [21,24,25] to date, making practitioners cautious about adopting FMT as a viable treatment alternative.”
BackgroundHamilton, M. J., Weingarden, A. R., Sadowsky, M. J., & Khoruts, A. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2011.482 · Cited by 738 · cited 1×
“The work of Hamilton and Khoruts [28] was used as a guide for fecal manipulation, with the exception that all processes were carried out under ambient air, not nitrogen.”
MethodBrandt, L. J., Aroniadis, O. C., Mellow, M., Kanatzar, A., Kelly, C., Park, T., Stollman, N., Rohlke, F., & Surawicz, C. (2012) · American Journal of Gastroenterology · doi:10.1038/ajg.2012.60 · Cited by 672 · cited 1×
“Fecal microbiota transplant (FMT)—reconstitution of normal flora by a stool transplant from a healthy individual—has been a successful therapeutic approach to recurrent/refractory CDI in animal studies [12], numerous case series [13–18], and, more recently, a single randomized clinical trial [19].”
BackgroundLawley, T. D., Clare, S., Walker, A. W., Stares, M. D., Connor, T. R., Raisen, C., Goulding, D., Rad, R., Schreiber, F., Brandt, C., et al. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002995 · Cited by 540 · cited 1×
“Fecal microbiota transplantation (FMT) reconstitution of normal flora by a stool transplant from a healthy individual - has been a successful therapeutic approach to recurrent/refractory CDI in animal studies [14], numerous case series [15–20] and, more recently, a single randomized clinical trial [21].”
BackgroundAas, J., Gessert, C. E., & Bakken, J. S. (2003) · Clinical Infectious Diseases · doi:10.1086/367657 · Cited by 518 · cited 1×
“Fecal microbiota transplant (FMT)—reconstitution of normal flora by a stool transplant from a healthy individual—has been a successful therapeutic approach to recurrent/refractory CDI in animal studies [12], numerous case series [13–18], and, more recently, a single randomized clinical trial [19].”
BackgroundMattila, E., Uusitalo–Seppälä, R., Wuorela, M., Lehtola, L., Nurmi, H., Ristikankare, M., Moilanen, V., Salminen, K., Seppälä, M., Mattila, P. S., et al. (2012) · Gastroenterology · doi:10.1053/j.gastro.2011.11.037 · Cited by 371 · cited 1×
“Fecal microbiota transplant (FMT)—reconstitution of normal flora by a stool transplant from a healthy individual—has been a successful therapeutic approach to recurrent/refractory CDI in animal studies [12], numerous case series [13–18], and, more recently, a single randomized clinical trial [19].”
BackgroundClostridium difficile Infection in Infants and Children
COMMITTEE ON INFECTIOUS DISEASES, Schutze, G. E., Willoughby, R. E., Brady, M. T., Byington, C. L., Davies, H. D., Edwards, K. M., Glode, M. P., Jackson, M. A., Keyserling, H. L., et al. (2013) · PEDIATRICS · doi:10.1542/peds.2012-2992 · Cited by 256
Vardakas, K. Z., Polyzos, K. A., Patouni, K., Rafailidis, P. I., Samonis, G., & Falagas, M. E. (2012) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2012.01.004 · Cited by 250 · cited 1×
“recurrence exceeds 60% with antimicrobial therapy [3, 5–8].”
BackgroundPepin, J., Routhier, S., Gagnon, S., & Brazeau, I. (2006) · Clinical Infectious Diseases · doi:10.1086/501126 · Cited by 246 · cited 1×
“recurrence exceeds 60% with antimicrobial therapy [3, 5–8].”
BackgroundThe Epidemiology of Clostridium difficile Infection in Children: A Population-Based Study
Khanna, S., Baddour, L. M., Huskins, W. C., Kammer, P. P., Faubion, W. A., Zinsmeister, A. R., Harmsen, W. S., & Pardi, D. S. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit075 · Cited by 209 · cited 2×
“matic increase in the number of patients globally [1–4].”
BackgroundKelly, C. R., de Leon, L., & Jasutkar, N. (2012) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e318234570b · Cited by 190 · cited 1×
“Fecal microbiota transplant (FMT)—reconstitution of normal flora by a stool transplant from a healthy individual—has been a successful therapeutic approach to recurrent/refractory CDI in animal studies [12], numerous case series [13–18], and, more recently, a single randomized clinical trial [19].”
BackgroundPetrella, L. A., Sambol, S. P., Cheknis, A., Nagaro, K., Kean, Y., Sears, P. S., Babakhani, F., Johnson, S., & Gerding, D. N. (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis430 · Cited by 189 · cited 1×
“The emergence of a virulent strain of the organism (NAP1/BI/027) has been associated with even higher rates of treatment failure [9,10].”
BackgroundPépin, J., Valiquette, L., Gagnon, S., Routhier, S., & Brazeau, I. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01539.x · Cited by 175 · cited 2×
“recurrence exceeds 60% with antimicrobial therapy [3, 5–8].”
BackgroundNational point prevalence of Clostridium difficile in US health care facility inpatients, 2008
Jarvis, W. R., Schlosser, J., Jarvis, A. A., & Chinn, R. (2009) · American Journal of Infection Control · doi:10.1016/j.ajic.2009.01.001 · Cited by 145
Guo, B., Harstall, C., Louie, T., Veldhuyzen van Zanten, S., & Dieleman, L. A. (2012) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2012.05033.x · Cited by 135 · cited 1×
“Even though an overall CDI resolution rate of about 90% has repeatedly been reported in published reviews and meta-analyses [20–23], practical and aesthetic barriers have hindered the widespread use of FMT to”
ResultClostridium difficile Infection in Children
Sammons, J. S., Toltzis, P., & Zaoutis, T. E. (2013) · JAMA Pediatrics · doi:10.1001/jamapediatrics.2013.441 · Cited by 126 · cited 1×
“matic increase in the number of patients globally [1–4].”
BackgroundFecal Microbiota Transplantation for Recurrent Clostridium difficile Infection
Brandt, L. J., & Reddy, S. S. (2011) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0b013e318222e603 · Cited by 98
Kelly, C. R., Kunde, S. S., & Khoruts, A. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2013.09.060 · Cited by 79 · cited 1×
“As mentioned, this limitation can be partly explained by the logistical hurdles associated with the procedure [31].”
BackgroundComputational Methods for High-Throughput Comparative Analyses of Natural Microbial Communities
Preheim, S. P., Perrotta, A. R., Friedman, J., Smillie, C. S., Brito, I., Smith, M. B., & Alm, E. J. (2013) · Methods in enzymology on CD-ROM/Methods in enzymology · doi:10.1016/b978-0-12-407863-5.00018-6 · Cited by 58 · cited 1×
“We used the Shannon Diversity Index as our primary measure of diversity because it takes into account both abundance and evenness of species present in the community and has been shown to most robustly accommodate the variation in sampling depth [31].”
MethodSelf-citationLaCourse, S. M., Chester, F. M., Preidis, G. A., McCrary, L. M., Arscott‐Mills, T., James, G., McCollum, E. D., & Hosseinipour, M. C. (2014) · Cited by 57
Fridey, J. L., Townsend, M. J., Kessler, D. A., & Gregory, K. R. (2007) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2007.03.001 · Cited by 37 · cited 1×
“Candidates were initially screened using the American Association of Blood Banks donor questionnaire for exposure to infectious agents [27], then underwent physical examination and general laboratory screening tests (within 30 days of donations), including complete blood count with differential, renal function and ele…”
MethodFecal transplantation for the treatment of recurrentClostridium difficileinfection
Karadsheh, Z., & Sule, S. S. (2013) · North American Journal of Medical Sciences · doi:10.4103/1947-2714.114163 · Cited by 29 · cited 1×
“Another inhibiting factor is the fact that the available data are mostly based on retrospective case series and include only a single randomized trial [21,24,25] to date, making practitioners cautious about adopting FMT as a viable treatment alternative.”
BackgroundRisk and rewards of fecal transplants
Glauser, W. (2011) · Canadian Medical Association Journal · doi:10.1503/cmaj.109-3806 · Cited by 9 · cited 1×
“Even though an overall CDI resolution rate of about 90% has repeatedly been reported in published reviews and meta-analyses [20–23], practical and aesthetic barriers have hindered the widespread use of FMT to”
ResultFecal microbiota transplantation for recurrent Clostridium difficile infection
Galindo, R. C., & Aranda, J. (2015) · Dipòsit Digital de Documents de la UAB (Universitat Autònoma de Barcelona) · Cited by 4
Research works printed but not linked: 1
- 2013, Clostridium difficile infection in children, JAMA Pediatr, 167, 567, 10.1001/jamapediatrics.2013.441 · DOI · Paper page
Cited by
McDonald, L. C., Gerding, D. N., Johnson, S., Bakken, J. S., Carroll, K. C., Coffin, S. E., Dubberke, E. R., Garey, K. W., Gould, C. V., Kelly, C., et al. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/cix1085 · Cited by 2,690
Kang, D.-W., Adams, J. B., Gregory, A. C., Borody, T., Chittick, L., Fasano, A., Khoruts, A., Geis, E., Maldonado, J., McDonough-Means, S., et al. (2017) · Microbiome · doi:10.1186/s40168-016-0225-7 · Cited by 1,391
European consensus conference on faecal microbiota transplantation in clinical practice
Cammarota, G., Ianiro, G., Tilg, H., Rajilić-Stojanović, M., Kump, P., Satokari, R., Sokol, H., Arkkila, P., Pintus, C., Hart, A., et al. (2017) · Gut · doi:10.1136/gutjnl-2016-313017 · Cited by 1,207
Meta-analysis of gut microbiome studies identifies disease-specific and shared responses
(2017) · doi:10.1038/s41467-017-01973-8 · Cited by 986
Self-citationFactors affecting the composition of the gut microbiota, and its modulation
Hasan, N., & Yang, H. (2019) · PeerJ · doi:10.7717/peerj.7502 · Cited by 755
Metadata
- Authors
- Youngster, I., Sauk, J., Pindar, C., Wilson, R. G., Kaplan, J. L., Smith, M. B., Alm, E. J., Gevers, D., Russell, G. H., & Hohmann, E. L.
- Affiliations
- Boston Children's Hospital (US)
- Harvard University (US)
- Massachusetts General Hospital (US)
- Broad Institute (US)
- Corresponding author
- Youngster, Ilan
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-04-23
- Volume
- 58
- Issue
- 11
- Pages
- 1515-1522
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- PMC
- PMC4017893
- OpenAlex
- W2146116383
- Cited by
- 467
- References
- 32
- Citations by year
- 2026: 7 · 2025: 15 · 2024: 31 · 2023: 22 · 2022: 24 · 2021: 35 · 2020: 37 · 2019: 51 · 2018: 47 · 2017: 57 · 2016: 53 · 2015: 61 · 2014: 27
- FWCI
- 46.23
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Infectious Diseases (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc-sa)
- Funders
- National Institutes of Health (UL1TR000170)
- National Institute of Allergy and Infectious Diseases (HHSN272200900018C)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30DK043351)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Infectious Diseases › Clostridium difficile and Clostridium perfringens research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- fecal microbiota transplantation, recurrent Clostridium difficile infection, unrelated donor, nasogastric tube administration, diarrhea resolution, health-related quality of life, antibiotic-refractory infection
- MeSH terms
- Adolescent, Adult, Aged, Aged, 80 and over, Biological Therapy, Child, Clostridium Infections, Colonoscopy, Diarrhea, Female, Humans, Intubation, Gastrointestinal, Male, Middle Aged, Pilot Projects, Surveys and Questionnaires, Recurrence, Clostridioides difficile, Treatment Outcome, Young Adult, Unrelated Donors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.